Reduces key pro-inflammatory markers, independent of amyloid beta or tau pathology Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or ...

InMed Pharmaceuticals Inc (NASDAQ:INM) shares are trading higher by 22.6% to $6.05 during Tuesday’s session after the company announced that INM-901 reduced Alzheimer’s-related inflammation in a ...

In vitro Alzheimer's disease studies show that INM-901 treated groups display neuroprotection and extended neurite length, a potential marker for improved neuronal function INM-901 treated groups in ...

InMed Pharmaceuticals (Nasdaq:INM) recently released preclinical data indicating its proprietary, small molecule compound, INM-901, targets multiple biological pathways associated with Alzheimer’s ...

InMed Pharmaceuticals Inc. (NASDAQ:INM) stock is surging early Tuesday, with a session volume of 6.63 million compared to the average volume of 1.31 million, as per data from Benzinga Pro. On Tuesday, ...

Shares of InMed Pharmaceuticals INM surged 36.33% at market close after the company announced the launch of its neurodegenerative disease program (INM-900 series), to investigate the effects of ...

InMed (NASDAQ: INM) stock rose 300% and change yesterday at one point. INM stock then fell back considerably on the announcement of a stock issue. Which is rather how this world of development pharma ...

The main entity that sells newspapers and advertising for Independent News and Media (INM) recorded a 7 per cent decline in sales last year to €81 million. INM, which was bought by Belgian group ...

THE parent firm of the Belfast Telegraph and Sunday Life has been sold to a Belgian media company at what some analysts believe is a knockdown price of €145.6 million (about £126 million). Independent ...